In 2019, we saw Asia developing itself into a major hub for medtech and biopharma activities for both local as well multinational companies. Biotech companies in the region entered into partnerships with leading global biopharmaceutical companies on both the R&D and commercial fronts. Now, as we enter into 2020, the industry plans to further rise in the medtech, biopharma and startups space within Asia focusing on applied research, new technologies, affordability and manageability.
